|
| 31109249 | Implementing a personalized medicine cancer program in a community cancer system. | Per Med | 2019 |
| 31339827 | Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. | J Clin Oncol | 2019 |
| 30983513 | Implementing pharmacogenetic testing in rural primary care practices: a pilot feasibility study. | Pharmacogenomics | 2019 |
| 30709424 | Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. | J Immunother Cancer | 2019 |
| 27895220 | Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. | J Oncol Pharm Pract | 2018 |
| 30345883 | Implementing a personalized medicine program in a community health system. | Pharmacogenomics | 2018 |
| 29460415 | Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. | Clin Pharmacol Ther | 2018 |
| 28294551 | The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. | Clin Transl Sci | 2017 |
| 25871653 | Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young age. | Clin Genet | 2016 |
| 26160883 | Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). | J Natl Cancer Inst | 2015 |
| 24495163 | Genomics education for the public: perspectives of genomic researchers and ELSI advisors. | Genet Test Mol Biomarkers | 2014 |
| 29751378 | Cancer pharmacogenomics, adoption by oncologists and patient benefit. | Per Med | 2014 |
| 24316779 | Integrating personalized genomic medicine into routine clinical care: addressing the social and policy issues of pharmacogenomic testing. | N C Med J | 2013 |
| 22198468 | Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). | Breast Cancer Res Treat | 2012 |
| 22649152 | Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. | J Clin Oncol | 2012 |
| 22676197 | Return of research results from pharmacogenomic versus disease susceptibility studies: what's drugs got to do with it? | Pharmacogenomics | 2012 |
| 22241094 | IRB perspectives on the return of individual results from genomic research. | Genet Med | 2012 |
| 22415847 | Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience. | Cancer | 2012 |
| 21693655 | p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). | Clin Cancer Res | 2011 |
| 21632745 | Ethical and practical challenges of sharing data from genome-wide association studies: the eMERGE Consortium experience. | Genome Res | 2011 |
| 20017668 | Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. | Pharmacogenomics | 2010 |
| 21169259 | Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. | Clin Cancer Res | 2010 |
| 20733502 | Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. | Genet Med | 2010 |
| 19470942 | Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. | J Clin Oncol | 2009 |
| 19844223 | How will GINA influence participation in pharmacogenomics research and clinical testing? | Clin Pharmacol Ther | 2009 |
| 19549775 | Disclosure of research results from cancer genomic studies: state of the science. | Clin Cancer Res | 2009 |
| 17578664 | Epidemiology of basal-like breast cancer. | Breast Cancer Res Treat | 2008 |
| 18390970 | Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. | J Clin Oncol | 2008 |
| 17301248 | Biospecimen "ownership": counterpoint. | Cancer Epidemiol Biomarkers Prev | 2007 |
| 17928597 | HER2 and response to paclitaxel in node-positive breast cancer. | N Engl J Med | 2007 |
| 16643655 | The molecular portraits of breast tumors are conserved across microarray platforms. | BMC Genomics | 2006 |
| 17085396 | Thresholds and boundaries in the disclosure of individual genetic research results. | Am J Bioeth | 2006 |
| 17129383 | Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. | Breast Cancer Res | 2006 |
| 16773437 | Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. | Breast Cancer Res Treat | 2006 |
| 16757721 | Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. | JAMA | 2006 |
| 16942640 | Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. | Clin Breast Cancer | 2006 |
| 15994142 | Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. | J Clin Oncol | 2005 |
| 15861214 | High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. | Mod Pathol | 2005 |
| 15144956 | Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. | Cancer Cell | 2004 |
| 15564794 | Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. | Breast Cancer Res Treat | 2004 |
| 15328174 | Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. | Clin Cancer Res | 2004 |
| 15361840 | Mutation of GATA3 in human breast tumors. | Oncogene | 2004 |
| 12846420 | HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. | Breast Cancer Res Treat | 2003 |
| 14575358 | Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States). | Cancer Causes Control | 2003 |
| 11929815 | Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. | Cancer Res | 2002 |
| 12223426 | Environmental factors in relation to breast cancer characterized by p53 protein expression. | Cancer Epidemiol Biomarkers Prev | 2002 |
| 12006505 | Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. | Clin Cancer Res | 2002 |
| 12090421 | Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer. | Am J Clin Pathol | 2002 |
| 11881772 | Nasal squamous cell carcinoma in a child. | J Otolaryngol | 2002 |
| 11678307 | Tumor characteristics in African American and white women. | Breast Cancer Res Treat | 2001 |